Prediction of therapeutic response in patients suffering from obsessive compulsive disorder resistant to the treatment with psychopharmacs;Predikce terapeutické odpovědi v kognitivně behaviorální terapii u pacientů s obsedantně kompulzivní poruchou rezistentní na léčbu psychofarmaky

Psychiatrie

Volumn 12, Issue SUPPL. 3, 2008, Pages 55-62

  Praško, Ján ^a,b,c,d   Raszka, Michal ^c,d,e   Adamcová, Katarína ^c   Kopřivová, Jana ^c,d,e   Kudrnovská, Hana ^c   Vyskočilová, Jana ^c  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^d Centrum Neuropsychiatrických Studií

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CBT; Dissociation; Insight; Obsessive compulsive disorder; prediction of treatment outcome; Resistance; SSRI

Indexed keywords

ADULT; AGGRESSION; AMBIVALENCE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISSOCIATION; DISSOCIATIVE EXPERIENCE SCALE; FEMALE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PREDICTION; QUESTIONNAIRE; RATING SCALE; REMISSION; SOMATOFORM DISSOCIATION QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 55249124574     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Abrahamowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65: 44-52.
2. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001; 62: 535-540.
3. Beck AT & Emery G. Anxiety disorders and phobias: A cognitive perspective. New York, Basic Books: 1985.
4. Bernstein EM, Putnam FW. Development, Reliability, and Validity of a Dissociation Scale. J. Nerv. Ment. Dis., 174 (12), 1986; 727-735.
5. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-632.
6. Davidson JTR a Connor KM. Treatment of anxiety disorders. In: Schatzberg AF a Nemeroff CB (eds): Textbook of psychopharmacology. American Psychiatric Press, Washington 2004; 913-934.
7. Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61(3):412-4.
8. Denys D, van Nieuwerburgh F, Deforce D, Westenberg HGM. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007; 68: 747-753.
9. Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, Emslie G, Carpenter D. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol. 2003; 13 Suppl 1: S19-S29.
10. Goodman WK, Rasmussen SA, Price LH et al. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). New Haven, CT, Yale University Department of Psychiatry, 1986.
11. Goff DC, Olin JA, Jenike MA, Baer L, Buttolph ML. Dissociative symptoms in patients with obsessive-compulsive disorder. J Nerv Ment Dis.1992; 180: 332-337.
12. Greist JH a Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173 (suppl 35): 64-70.
13. Greist JH, Bandelow B, Hollander E et al. Long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums 2003; 8: 7-16.
14. Guy W (ed.). ECDEU Assessment manual for psychopharmacology. Rockville, U.S. DHEW 1976.
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
16. Hantouche EG, Bouhassira M, Lancrenon S. Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study. Encephale. 2000; 26: 73-83.
17. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive - compulsive disorder. Psychiatric Services 2003; 54 (8): 1111-1118.
18. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005 ;66(3):353-359.
19. Lecrubier Y, Sheehan DV, and Weiller E, et al. The MINI-international neuropsychiatric interview (M.I.N.I.): a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997; 12: 224-231.
20. Leonard HL, Swedo SE, Lenane MC, Rettew DC, Hamburger SD, Bartko JJ, Rapoport JL. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry. 1993; 50: 429-439.
21. March JS, Frances A, Kahn DA, Carpenter D. The expert consensus guidelines series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58: (Suppl): 1-72.
22. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999; 156: 1409-1416.
23. McDougle CJ, Fleischmann RL, Epperson CN, Wayslink S, Leckmann JF, Price LH. Risperidone addition in fluvoxamine refractory obsessive compulsive disorder: three cases. J Clin Psychiat 1995; 56: 526-528.
24. Mezinárodní klasifikace nemocí. 10.revize. Duševní poruchy a poruchy chování: Diagnostická kritéria pro výzkum. (přeloženo z anglického originálu) Praha, Psychiatrické centrum 1996, Zprávy č. 134, 179s.
25. Nakao T, Nakatani E, Nabeyama M, Yoshioka K, Tomita M, Nakagawa A: Duration effect on neuropsychological function and treatment response of OCD. Seishin Shinkeigaku Zasshi; 2005 ; 107: 1286-1298.
26. NICE 2006. Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body-dysmorphic disorder. National Collaborating Centre for Mental Health, Publ British Psychological Society and the Royal College of Psychiatrists, UK 2006. Also www.nice.org.uk.
27. Nijenhuis ERS, Spinhoven Ph. Van Dyck R, Van Der Hart O. Vanderlinden J. Somatoform Dissociation Questionaire. J. Nerv. Ment. Dis., 184 (11), 1996; 688-694.
28. Perse T. Obsessive-compulsive disorder: A treatment review. J Clin Psychiatry. 1988; 49: 48-55.
29. Pigott TA, Seay S. Pharmacotherapy of obsessive-compulsive disorder. Int Rev Psychiatry 1997; 9: 133-147.
30. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995; 56: 368-373.
31. Rufer M, Held D, Cremer J, Fricke S, Moritz S, Peter H, Hand I. Dissociation as a predictor of cognitive behavior therapy outcome in patients with obsessive-compulsive disorder. Psychother Psychosom. 2006; 75: 40-46.
32. Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, Tarlow G, Bystritsky A. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry. 2002; 63: 21-27.
33. Saxena S, Brody AL, Maidment KM, Baxter LR Jr. Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 2007;41: 481-487.
34. Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU, Raghunandanan S. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry. 2005; 66: 1517-1523.
35. Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, Davies SO, Campeas R. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004;19:225-233.
36. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008; 23;(1):CD001765.
37. Stewart SE, Stack DE, Wilhelm S. Severe obsessive-compulsive disorder with and without body dysmorphic disorder: clinical correlates and implications. Ann Clin Psychiatry. 2008; 20: 33-38.
38. Watson D, Wu KD, Cutshall C. Symptom subtypes of obsessive-compulsive disorder and their relation to dissociation. J Anxiety Disord 2004; 18: 435-58.
39. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive - compulsive disorder. J Clin Psychiatry 1994; 55 (3, suppl): 5-10.
40. Zohar J, Hollander E, Stein DJ et al. Cape Town consensus of the treatment of obsessive compulsive disorder. CNS Spectrums 2007; 2 (suppl 3): 59-63.